Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.

This study has been completed.
Sponsor:
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184353
First received: September 13, 2005
Last updated: October 20, 2011
Last verified: October 2011
  Purpose

Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and spectral resolution. To investigate this, spectra from different subjects were examined using two clinical MR instruments operating at 1.5T and 3T respectively.


Condition
Neoplasm Metastases

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: In Vivo Proton MR Spectroscopy of Brain Metastases Obtained at 1,5T and 3T.

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Enrollment: 19
Study Start Date: November 2003
Study Completion Date: June 2005
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts
brain metastases
6 patients
healthy
13 volunteers

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with brain metastases

Criteria

Inclusion Criteria:

  • brain metastases

Exclusion Criteria:

  • children
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184353

Locations
Norway
Norwegian University of Science and Technology
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Study Chair: Ingrid S Gribbestad, PhD Norwegian University of Science and Technology, Faculty of Medicine
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184353     History of Changes
Other Study ID Numbers: 173-03
Study First Received: September 13, 2005
Last Updated: October 20, 2011
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
brain metastasis
signal to noise ratio
spectral resolution

Additional relevant MeSH terms:
Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Brain Neoplasms
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on July 28, 2014